38183-04-9

Usage

Uses

Used in Pharmaceutical Industry:
6,7-Dihydroxyflavone is used as a key intermediate compound for the synthesis of chromenone derivatives with biphenyl, which are valuable in the prevention or treatment of allergic diseases. Its incorporation into these derivatives enhances their anti-allergic properties, making it a significant contributor to the development of novel therapeutic agents for allergy management.
Used in Chemical Synthesis:
6,7-Dihydroxyflavone serves as a versatile building block in the synthesis of various flavonoid-based compounds with potential applications in different industries, such as pharmaceuticals, cosmetics, and agriculture. Its unique structure allows for further functionalization and modification, leading to the creation of new molecules with improved properties and enhanced biological activities.

InChI:InChI=1/C15H10O4/c16-11-7-14(9-4-2-1-3-5-9)19-15-8-13(18)12(17)6-10(11)15/h1-8,17-18H

Upstream product

• 533-73-3 1,2,4-Trihydroxybenzene 
• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 525-82-6 FLAVONE 
• 6665-86-7 7-hydroxyflavone 
• 613-03-6 1,2,4-triacetoxybenzene 
• 1818-27-5 1-(2,4,5-trihydroxyphenyl)ethanone 
• 93-97-0 benzoic acid anhydride 

Downstream Products

• 94307-79-6 6,7-diacetoxyflavone 

Relevant academic research and scientific papers

Novel chromenone derivatives having substituted biphenyl group and a pharmaceutical composition for prevention or treatment of allergic diseases compring the same

The present invention relates to: a novel chromenone derivative compound capable of effectively suppressing an allergic immune response by inhibiting signal transduction mediated by thymic stromal lymphopoietin (TSLP); and a pharmaceutical composition capable of fundamentally preventing or treating various allergic diseases by using the same.COPYRIGHT KIPO 2021

COMPOUNDS FOR IMMUNOPOTENTIATION

Methods of stimulating an immune response and treating patients responsive thereto with 3,4-di(1H-indol-3-yl)-1H-pyrrole-2,5-diones, staurosporine analogs, derivatized pyridazines, chromen-4-ones, indolinones, quinazolines, nucleoside analogs, and other small molecules are disclosed.

Structure-activity relationships for α-glucosidase inhibition of baicalein, 5,6,7-trihydroxyflavone: The effect of A-ring substitution

In order to estimate the effects of the A-ring hydroxyl group of baicalein (5,6,7-trihydroxyflavone, 1) on rat intestinal α-glucosidase inhibition, flavone, monohydroxyflavones, dihydroxyflavones, and methylated derivatives of 5,6,7-trihydroxyflavone were used for the structure-activity relationship (SAR) study. The importance of the 6-hydroxyl group of baicalein was validated for an exertion of the activity. And also, the tested flavones which lacked a hydroxyl substituent on any of positions 5, 6, or 7, showed no activity. Hence, the 5,6,7-trihydroxyflavone structure was concluded to be crucial for the potent inhibitory activity. In addition, an introduction of electron-withdrawing or electron-donating groups at position 8 of baicalein led to a dramatic decrease for activity, except for 8-fluoro-5,6,7-trihydroxyflavone, which carried a less bulky substituent on position 8. Hence, this result suggested that a sterically bulky substituent on C-8 of baicalein was detrimental for the activity regardless of its electronic nature. Through examining the inhibitory mechanism of baicalein against rat intestinal α-glucosidase, it was suggested to be a mixed type inhibition.